

**Mass General Brigham  
Incorporated and Affiliates**  
Consolidated Financial Statements  
September 30, 2025 and 2024



# Mass General Brigham Incorporated and Affiliates

## Index

September 30, 2025 and 2024

---

	Page(s)
<b>Report of Independent Auditors .....</b>	<b>1–2</b>
<b>Consolidated Financial Statements</b>	
Consolidated Balance Sheets .....	3
Consolidated Statements of Operations .....	4
Consolidated Statements of Changes in Net Assets .....	5
Consolidated Statements of Cash Flows .....	6
Notes to Consolidated Financial Statements .....	7–48





## **Report of Independent Auditors**

To the Board of Directors of Mass General Brigham Incorporated

### ***Opinion***

We have audited the accompanying consolidated financial statements of Mass General Brigham Incorporated (the "Company") and its affiliates, which comprise the consolidated balance sheets as of September 30, 2025 and 2024, and the related consolidated statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company and its affiliates as of September 30, 2025 and 2024, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

### ***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and its affiliates and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Responsibilities of Management for the Consolidated Financial Statements***

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates' ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

### ***Auditors' Responsibilities for the Audit of the Consolidated Financial Statements***

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates' ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

*PricewaterhouseCoopers LLP*

Boston, Massachusetts  
December 19, 2025



**Mass General Brigham Incorporated and Affiliates**  
**Consolidated Balance Sheets**  
**September 30, 2025 and 2024**

(in thousands of dollars)

	2025	2024
<b>Assets</b>		
Current assets		
Cash and equivalents	\$ 529,648	\$ 105,924
Investments	4,660,478	4,479,974
Current portion of investments limited as to use	3,364,140	3,651,727
Patient accounts receivable, net	1,774,269	1,731,496
Research grants receivable, net	429,227	248,415
Other current assets	1,390,446	1,205,371
Total current assets	12,148,208	11,422,907
Investments limited as to use, less current portion	7,404,116	6,443,033
Long-term investments	3,941,173	3,138,592
Property and equipment, net	7,829,880	7,471,740
Right-of-use operating lease assets	801,815	920,702
Other assets	3,703,237	2,360,443
Total assets	<u>\$ 35,828,429</u>	<u>\$ 31,757,417</u>
<b>Liabilities and Net Assets</b>		
Current liabilities		
Current portion of long-term obligations	\$ 448,435	\$ 353,249
Accounts payable and accrued expenses	1,276,076	1,426,104
Accrued medical claims and related expenses	215,581	258,520
Accrued employee compensation and benefits	1,414,617	1,281,714
Current portion of operating lease obligations	155,897	203,879
Unexpended funds on research grants	469,114	369,851
Total current liabilities	3,979,720	3,893,317
Accrued professional liability	594,421	573,796
Accrued employee benefits	990,808	891,868
Interest rate swaps liability	85,312	139,170
Accrued other	421,081	463,907
Operating lease obligations, less current portion	545,738	598,065
Long-term obligations, less current portion	5,599,780	5,837,579
Total liabilities	<u>12,216,860</u>	<u>12,397,702</u>
Commitments and contingencies		
Net assets		
Net assets without donor restrictions	18,874,645	15,306,802
Noncontrolling ownership interests in subsidiaries	93,653	106,788
Total net assets without donor restrictions	18,968,298	15,413,590
With donor restrictions	4,643,271	3,946,125
Total net assets	<u>23,611,569</u>	<u>19,359,715</u>
Total liabilities and net assets	<u>\$ 35,828,429</u>	<u>\$ 31,757,417</u>

The accompanying notes are an integral part of these consolidated financial statements.



**Mass General Brigham Incorporated and Affiliates**  
**Consolidated Statements of Operations**  
**Years Ended September 30, 2025 and 2024**

*(in thousands of dollars)*

	<b>2025</b>	<b>2024</b>
<b>Operating revenues</b>		
Net patient service revenue	\$ 14,480,064	\$ 13,439,956
Premium revenue	2,537,401	2,169,968
Direct research and nonresearch sundry revenue	2,324,147	2,240,832
Indirect research and nonresearch sundry revenue	716,296	659,918
Other revenue	2,749,861	2,039,604
Total operating revenues	<u>22,807,769</u>	<u>20,550,278</u>
<b>Operating expenses</b>		
Employee compensation and benefit expenses	11,122,914	10,264,778
Supplies and other expenses	6,524,901	5,540,276
Medical claims and related expenses	1,819,473	1,505,038
Direct research and nonresearch sundry expenses	2,324,147	2,240,832
Depreciation and amortization expenses	791,752	778,337
Interest expense	165,406	175,279
Total operating expenses	<u>22,748,593</u>	<u>20,504,540</u>
Income from operations	<u>59,176</u>	<u>45,738</u>
<b>Nonoperating gains (loss)</b>		
Income from investments	1,751,132	1,950,070
Change in fair value of interest rate swaps	84,167	(84,228)
Other nonoperating expenses	(3,512)	(38,624)
Research and nonresearch sundry gifts net of spending	257,903	(48,187)
Nonservice related pension income	236,776	222,910
Total nonoperating gains, net	<u>2,326,466</u>	<u>2,001,941</u>
Excess of revenues over expenses	2,385,642	2,047,679
<b>Other changes in net assets</b>		
Funds utilized for property and equipment	36,549	434,073
Change in funded status of defined benefit plans	1,135,994	(445,729)
Other changes in net assets	(3,477)	15,122
Increase in net assets without donor restrictions	<u>\$ 3,554,708</u>	<u>\$ 2,051,145</u>

The accompanying notes are an integral part of these consolidated financial statements.



**Mass General Brigham Incorporated and Affiliates**  
**Consolidated Statements of Changes in Net Assets**  
**Years Ended September 30, 2025 and 2024**

<i>(in thousands of dollars)</i>	<b>Without Donor Restrictions</b>	<b>With Donor Restrictions</b>	<b>Total</b>
<b>Net assets at September 30, 2023</b>	<b>\$ 13,362,445</b>	<b>\$ 3,739,156</b>	<b>\$ 17,101,601</b>
Increases (decreases)			
Income from operations	45,738	-	45,738
Income from investments	1,950,070	356,508	2,306,578
Change in fair value of interest rate swaps	(84,228)	-	(84,228)
Other nonoperating (expenses) income	(38,624)	240,919	202,295
Research and nonresearch sundry gifts net of spending	(48,187)	-	(48,187)
Nonservice related pension income	222,910	-	222,910
Funds utilized for property and equipment	434,073	(393,305)	40,768
Change in funded status of defined benefit plans	(445,729)	-	(445,729)
Other changes in net assets	15,122	2,847	17,969
Change in net assets	2,051,145	206,969	2,258,114
<b>Net assets at September 30, 2024</b>	<b>15,413,590</b>	<b>3,946,125</b>	<b>19,359,715</b>
Increases (decreases)			
Income from operations	59,176	-	59,176
Income from investments	1,751,132	284,594	2,035,726
Change in fair value of interest rate swaps	84,167	-	84,167
Other nonoperating (expenses) income	(3,512)	435,519	432,007
Research and nonresearch sundry gifts net of spending	257,903	-	257,903
Nonservice related pension income	236,776	-	236,776
Funds utilized for property and equipment	36,549	(25,516)	11,033
Change in funded status of defined benefit plans	1,135,994	-	1,135,994
Other changes in net assets	(3,477)	2,549	(928)
Change in net assets	3,554,708	697,146	4,251,854
<b>Net assets at September 30, 2025</b>	<b>\$ 18,968,298</b>	<b>\$ 4,643,271</b>	<b>\$ 23,611,569</b>

The accompanying notes are an integral part of these consolidated financial statements.



# Mass General Brigham Incorporated and Affiliates

## Consolidated Statements of Cash Flows

### Years Ended September 30, 2025 and 2024

(in thousands of dollars)

	2025	2024
<b>Cash flows from operating activities</b>		
Change in net assets	\$ 4,251,854	\$ 2,258,114
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Change in funded status of defined benefit plans	(1,135,994)	445,729
Gain on refunding of debt	-	(7,010)
Change in fair value of interest rate swaps	(84,167)	84,228
Depreciation and amortization	791,752	778,337
Amortization of bond discount, premium and issuance costs	(17,862)	(11,164)
(Gain) loss on disposal of property	(3,636)	324
Change in right-of-use operating lease assets	178,045	120,409
Net realized and unrealized change in investments	(2,407,738)	(2,570,863)
Donor restricted contributions and investment income	(428,885)	(292,309)
Cash premium received upon issuance of bonds	-	34,049
Increases (decreases) in cash resulting from a change in		
Patient accounts receivable	(42,773)	(93,190)
Other assets	(498,881)	(371,302)
Accounts payable and other accrued expenses	166,265	378,627
Accrued medical claims and related expenses	(42,939)	66,085
Operating lease obligations	(159,467)	(119,242)
Settlements with third-party payers	(52,882)	185,245
Net cash provided by operating activities	512,692	886,067
<b>Cash flows from investing activities</b>		
Purchases of property and equipment	(1,174,376)	(1,492,907)
Proceeds from sale of property	4,329	1,392
Purchase of investments	(1,387,071)	(1,734,338)
Proceeds from sales of investments	2,138,228	1,649,745
Net cash used for investing activities	(418,890)	(1,576,108)
<b>Cash flows from financing activities</b>		
Borrowings under taxable commercial paper	171,842	-
Repayments of borrowings under taxable commercial paper	(109,907)	(119,870)
Borrowings under lines of credit	625,000	270,000
Repayments of borrowings under lines of credit	(625,000)	(270,000)
Payments on long-term obligations	(124,751)	(110,891)
Proceeds from long-term obligations	-	524,802
Deposits into refunding trusts	(61,935)	(69,844)
Net gain on interest rate swap terminations	25,788	-
Donor restricted contributions and investment income	428,885	292,309
Net cash provided by financing activities	329,922	516,506
Net increase (decrease) in cash and equivalents	423,724	(173,535)
<b>Cash and equivalents</b>		
Beginning of year	105,924	279,459
End of year	\$ 529,648	\$ 105,924
Noncash purchases of property and equipment in accounts payable and accrued expenses	\$ 86,288	\$ 110,631

The accompanying notes are an integral part of these consolidated financial statements.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

(in thousands of dollars)

#### 1. Organization and Community Benefit Commitments

Mass General Brigham Incorporated (the Company) is the parent organization and sole corporate member of numerous organizations whose financial condition and operations are described in these consolidated financial statements. The terms Mass General Brigham, We, Our or Us as used herein, unless otherwise stated or indicated by context, refer collectively to the Company and its affiliated organizations.

Mass General Brigham operates academic medical centers, community acute care hospitals, inpatient and outpatient mental health services facilities, urgent care centers, facilities that provide rehabilitation medicine and long-term care services, physician organizations, home health services, nursing homes and a graduate level program for health professions. Our mission is to provide world class health care services to the local communities in which we operate as well as to patients across the United States and the world. In addition, we are a nonuniversity-based nonprofit private medical research enterprise and a principal teaching affiliate of the medical and dental schools of Harvard University. Our licensed, not-for-profit managed care organization (Mass General Brigham Health Plan, Inc.) and licensed, for-profit insurance company (Mass General Brigham Health Insurance Company) (collectively referred to as the Health Plan) provide health insurance products and administrative services to the Massachusetts Medicaid program (MassHealth), Medicare Advantage program, ConnectorCare (a state subsidized program for adults who meet income and immigration guidelines) and commercial populations.

#### Community Health

The Mass General Brigham *Health Equity & Community Health* program aims to make measurable, impactful and sustainable improvements in clinical equity for our patients, along with better health outcomes for the communities we serve.

We are focused on health conditions that are the greatest contributor to premature mortality and reduced life expectancy in these communities: cardiometabolic disease (including hypertension and diabetes), substance use disorder, cancer and maternal-child health.

We are committed to addressing the root causes of health disparities by building and strengthening our community-based partnerships to make the greatest impact on issues such as food insecurity, housing instability, limited economic mobility and educational opportunities, and barriers to accessing care.

#### Charity Care

We provide charity care to all emergent patients regardless of their ability to pay. The cost of and reimbursement for providing that care, as reflected in the consolidated statements of operations, is summarized below.

#### State Programs

##### **Massachusetts**

Acute care hospitals in The Commonwealth of Massachusetts (the Commonwealth or Massachusetts) are partially reimbursed for charity care services through the statewide Health Safety Net Trust Fund (HSN). A portion of the funding for the HSN is paid by an assessment on acute care hospitals' charges for private sector payers. The statewide assessment was \$163,784 and \$165,231 in 2025 and 2024, respectively, and the assessment expense on our acute care hospitals was \$57,819 in both 2025 and 2024.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

Acute care hospitals are reimbursed for charity care based on claims for eligible patients and services that are submitted to and adjudicated by the HSN. Payments are based on Medicare rates and payment policies. The Commonwealth reported that HSN was under-funded by approximately \$284,292 and \$133,027 as of September 30, 2025 and 2024, respectively. This shortfall is allocated to acute care hospitals based on their share of total statewide patient care costs. We have estimated our share being approximately \$105,445 and \$67,980 as of September 30, 2025 and 2024, respectively. The Commonwealth passed a hospital relief package in 2025 that included \$77,000 for statewide HSN shortfall relief of which \$4,104 was paid to and recognized by us. In 2025, there was no net HSN reimbursement recognized due to the HSN shortfall, resulting in no cost of charity care coverage. In 2024, our acute care hospitals received charity care funding covering 14% of the estimated cost of charity care provided.

The Commonwealth levies an additional assessment on Massachusetts acute care hospitals that is redistributed back to hospitals based on provisions within the MassHealth Section 1115 Demonstration. A new five-year waiver period began effective October 1, 2022. The total assessment was \$1,290,493 and \$709,685 in 2025 and 2024, respectively, and our assessment expense was \$294,968 and \$197,473 in 2025 and 2024, respectively. The total amount redistributed to hospitals across Massachusetts was \$2,338,288 and \$1,613,052 in 2025 and 2024, respectively, of which we recognized \$285,829 and \$179,114 in 2025 and 2024, respectively.

There is an assessment for our post-acute hospitals which totaled \$14,072 and \$5,756 in 2025 and 2024, respectively.

#### ***New Hampshire***

The State of New Hampshire (New Hampshire) imposes a Medicaid Enhancement Tax (MET) on hospital net patient service revenue. For both of New Hampshire's fiscal years ended June 30, 2025 and 2024, the MET imposed was 5.4%. We incurred \$32,578 and \$30,343 of MET in 2025 and 2024, respectively.

In 2025, New Hampshire acute care hospitals received direct inpatient and outpatient payments, inpatient service rate increases and disproportionate share payments based on a settlement agreement reached between New Hampshire and the New Hampshire state hospitals. We received \$11,139 in 2025. In 2024, New Hampshire acute care hospitals received disproportionate share payments based on a portion of their charity care relative to other acute care hospitals. We received \$17,582 in 2024.

#### ***Medicaid***

Medicaid is a health insurance program jointly funded by the states and the federal government. Each state administers its own program and sets rules for eligibility, benefits and provider payments within broad federal guidelines and in some cases, including the Commonwealth and New Hampshire, within a Waiver Agreement between each state and the federal government. The program provides health care coverage to low-income adults and children. Eligibility is determined by a variety of factors which include income relative to the federal poverty line, age, immigrant status and assets.

Medicaid payments to our providers do not cover the full cost of services provided to Medicaid patients. In aggregate, our reimbursement from Medicaid covered approximately 62% and 64% of the estimated cost of services that we provided in 2025 and 2024, respectively.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

(in thousands of dollars)

Mass General Brigham Health Plan, Inc. has an Accountable Care Organization (ACO) contract with the Executive Office of Health and Human Services of the Commonwealth (EOHHS) covering MassHealth members whose providers participate in the Mass General Brigham ACO.

#### Federal Program

##### Medicare

Medicare is a federally sponsored health insurance program for people age 65 or older, under age 65 with certain disabilities and any age with End-Stage Renal Disease. Medicare's payments historically have not kept pace with increases in the cost of care provided at many hospitals. Compounding this shortfall in payments is the continued shift of care from higher paying inpatient services to lower paying outpatient services.

Consequently, Medicare payments to our providers do not cover the full cost of services provided. In aggregate, our reimbursement from Medicare covered approximately 70% and 71% of the estimated cost of services that we provided in 2025 and 2024, respectively.

Mass General Brigham Health Plan, Inc. is authorized by the Centers for Medicare & Medicaid Services (CMS) to offer Medicare Advantage products to its eligible members.

#### Summary

For charity care, Medicaid and Medicare, the estimated cost of services provided is either obtained directly from a costing system or based on an entity specific ratio of cost to gross charges. In the latter case, cost is derived by applying this ratio to gross charges associated with providing care to charity care, Medicaid and Medicare patients. The following summarizes, by program, the cost of services provided, net reimbursement and cost of services in excess of reimbursement for each year:

	<b>Years Ended September 30,</b>	
	<b>2025</b>	<b>2024</b>
<b>Cost of services provided</b>		
Charity care	\$ 169,148	\$ 171,217
Medicaid	2,196,782	2,002,532
Medicare	6,427,357	5,780,976
	<u>\$ 8,793,287</u>	<u>\$ 7,954,725</u>
<b>Net reimbursement</b>		
Charity care reimbursement (shortfall absorption)	\$ (8,184)	\$ 20,259
Medicaid	1,365,114	1,285,520
Medicare	4,518,303	4,110,328
	<u>\$ 5,875,233</u>	<u>\$ 5,416,107</u>
<b>Cost of services in excess of reimbursement</b>		
Charity care	\$ 177,332	\$ 150,958
Medicaid	831,668	717,012
Medicare	1,909,054	1,670,648
	<u>\$ 2,918,054</u>	<u>\$ 2,538,618</u>



# **Mass General Brigham Incorporated and Affiliates**

## **Notes to Consolidated Financial Statements**

### **September 30, 2025 and 2024**

---

*(in thousands of dollars)*

In addition, there are significant losses related to self-pay patients who fail to make payment for services rendered or insured patients who fail to remit co-payments and deductibles as required under the applicable health insurance arrangement. The estimated cost of providing these services was approximately \$114,760 and \$105,896 for 2025 and 2024, respectively.

## **2. Summary of Significant Accounting Policies**

### **Basis of Accounting**

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting and include the accounts of the Company and its affiliates. Interaffiliate accounts and transactions have been eliminated.

### **Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are made in the areas of patient accounts receivable, research grants receivable, investments, receivables and accrual for settlements with third-party payers, accrued medical claims and related expenses, accrued employee compensation and benefits, accrued professional liability, interest rate swaps liability and accrued other.

### **Income Taxes**

The Company and substantially all of its affiliates are tax-exempt organizations under Sections 501(c)(3) or 501(c)(4) of the Internal Revenue Code (IRC) or are disregarded entities for tax purposes and therefore are exempt from federal and state income tax except on unrelated business taxable income. No provision for income taxes related to these tax-exempt entities has been made as the effect of any unrelated business income tax is not material to the accompanying consolidated financial statements.

### **Fair Value of Financial Instruments**

The fair value of financial instruments approximates the carrying amount reported in the consolidated balance sheets for cash and equivalents, investments and investments limited as to use, patient accounts receivable, research grants receivable, accounts payable and accrued expenses and interest rate swaps liability.

### **Cash and Equivalents**

Cash and equivalents represent cash, registered money market funds and highly liquid debt instruments with a maturity at the date of purchase of three months or less. Our cash and equivalents are maintained with several national banks, and cash deposits typically exceed federal insurance limits. Our policy is to monitor these banks' financial strength on an ongoing basis, and no losses have been experienced to date.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

(in thousands of dollars)

#### Investments

Investments in equity securities with readily determinable fair values, debt securities and alternative investments are measured at fair value. Alternative investments, consisting of various hedge funds, private equity funds, private debt funds, other private partnerships and restricted securities of public companies that are not traded on a national securities exchange, are valued based on amounts reported by the fund manager and evaluated by management. Investments in securities sold short or traded on a national securities exchange are valued based on quoted market prices.

Income from investments (including realized gains and losses, unrealized change in value of investments, interest, dividends and endowment income distributions) is included in excess of revenues over expenses unless the income or loss is restricted by donor or law. Income from investments is reported net of investment-related expenses.

Each year as part of our endowment spending policy, we establish a fixed distribution rate for spending. Distributions will come from either income and/or net accumulated appreciation. Our endowment spending policy is based on the Tobin Distribution Rule. The Tobin Distribution Rule sets the annual distribution through a quantitative formula that has a stability term (a percentage of the prior year's spending, adjusted for inflation) and a market term (a percentage of the long-term sustainable rate of distribution times the market value of the endowment).

#### Investments Limited as to Use

Investments limited as to use primarily include assets whose use is contractually limited by external parties as well as assets set aside by the boards (or management) for identified purposes and over which the boards (or management) retain control such that the boards (or management) may, at their discretion, subsequently use such assets for other purposes. Certain investments corresponding to deferred compensation are accounted for such that all income and appreciation (depreciation) is recorded as a direct addition (reduction) to the asset and corresponding liability.

#### Investment Companies

Certain investment companies are required to be consolidated for financial reporting purposes. Where such entities are not wholly owned by the Company, the portion of the consolidated entity's net assets that is not owned by the Company is disclosed as a non-controlling interest (Note 18). The fair value of consolidated investment company assets and liabilities included in the Company's consolidated financial statements are as follows:

	<b>September 30,</b>	
	<b>2025</b>	<b>2024</b>
Consolidated investment company assets	\$ 128,812	\$ 132,605
Consolidated investment company liabilities	3,000	1,315

#### Derivative Instruments

Derivatives are recognized on the balance sheets at fair value with changes in the fair value recorded in excess of revenues over expenses.

#### Patient Accounts Receivable

The payments received for health care services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care payers, commercial insurance companies and patients are subject to explicit and implicit discounts. These discounts are based on



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

contractual agreements, discount policies and management's assessment of historical experiences and are reflected in the period of service.

#### **Research Grants Receivable**

Mass General Brigham receives direct and pass-through research funding from the National Institutes for Health and other federal agencies, industry, corporate, foundation, nonprofits and other sponsors. Research grants receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor, or in limited circumstances, represent accelerated spending in anticipation of future funding. Research grants receivable are recognized at net realizable value.

As of September 30, 2025 and 2024, we have approximately \$4,280,855 and \$4,598,252, respectively, of conditional research grants for future research to be performed. The timing and amounts of funds received under such grants are subject to continued government funding and may change over time.

#### **Other Current Assets**

Other current assets include prepaid expenses, inventory, nonpatient receivables, current portion of receivable for settlements with third-party payers, current portion of pledges receivable and premiums receivable. Inventory (primarily supplies and pharmaceuticals) is accounted for on a first-in, first-out method basis and is recorded at the lower of average weighted cost or net realizable value.

#### **Property and Equipment**

Property and equipment is reported on the basis of cost less accumulated depreciation. Donated items are recorded at fair value at the date of contribution. All research grants received for capital are recorded in the year of expenditure as a change in net assets without donor restrictions. Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Depreciation of property and equipment is calculated by use of the straight-line method at rates intended to depreciate the cost of assets over their estimated useful lives, which generally range from three to fifty years. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized, net of any interest earned, as a component of the cost of acquiring those assets.

#### **Asset Retirement Obligations**

Asset retirement obligations, reported in accrued other, are legal obligations associated with the retirement of long-lived assets. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Any changes to the liability due either to the passage of time, better information or the settlement of an obligation are reflected in the current period.

#### **Other Assets**

Other assets consist of long-term receivables, intangible assets, malpractice insurance receivables, receivable for settlements with third-party payers, investments in health care related limited partnerships, long-term pledges and contributions receivable and defined benefit pension plan and postretirement health care benefit plan assets in excess of plan benefit obligations. The carrying value of other assets is evaluated for impairment if the facts and circumstances suggest that the carrying value may not be recoverable.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

#### **Compensated Absences**

In accordance with formal policies concerning vacation and other compensated absences, accruals of \$478,271 and \$443,417 were recorded as of September 30, 2025 and 2024, respectively.

#### **Unexpended Funds on Research Grants**

Research grants received in advance of corresponding grant expenditures are accounted for as a direct addition to investments limited as to use and unexpended funds on research grants.

#### **Self-Insurance Reserves**

We are generally self-insured for employee health care, disability, workers' compensation and certain other employee benefits. These costs are accounted for on an accrual basis to include estimates of future payments for claims incurred prior to year-end and are included in accrued employee compensation and benefits and long-term accrued employee benefits.

#### **Net Assets**

Net assets with donor restrictions include (a) the historical dollar amounts of contributions and the income and gains on such contributions which are required by donors to be retained and (b) contributions and the income and gains on these contributions which can be expended but for which restrictions have not yet been met. Such restrictions include purpose restrictions where donors have specified the purpose for which the net assets are to be spent, or time restrictions imposed by donors or implied by the nature of the contribution (capital projects, pledges to be paid in the future and life income funds) or by interpretations of law (gains available for appropriation but not appropriated in the current period). All remaining net assets are considered to be without donor restrictions.

Realized gains and losses are classified as net assets without donor restrictions unless they are restricted by the donor or law. Realized gains and net unrealized appreciation on contributions with donor restrictions are classified as net assets with donor restrictions until appropriated for spending in accordance with policies established by Mass General Brigham and applicable provisions of the Uniform Prudent Management of Institutional Funds Acts (UPMIFA). Net losses on donor endowment funds with donor restrictions are classified as a reduction to net assets with donor restrictions.

#### **Contributed Securities**

Our policy is to sell securities contributed by donors upon receipt, unless prevented from doing so by donor request. For the years ended September 30, 2025 and 2024, contributed securities of \$227,665 and \$146,236, respectively, were received and liquidated. Donors restricted \$171,758 and \$85,180 of the proceeds received from the sale of these contributed securities for long-term purpose for the years ended September 30, 2025 and 2024, respectively.

#### **Statement of Operations**

Activities deemed by management to be ongoing, major and central to the provision of health care services, teaching, research activities and health insurance are reported as operating revenues and expenses. Other activities are deemed to be nonoperating and include contributions without donor restrictions (net of fundraising expenses), external community benefit program support, net change in unexpended research and nonresearch sundry contributions, change in fair value of interest rate swaps, substantially all income from investments, interest on advanced borrowings and nonservice related pension income. Research and nonresearch sundry contributions largely consist of donor contributions (and the related investment income including realized gains and



# **Mass General Brigham Incorporated and Affiliates**

## **Notes to Consolidated Financial Statements**

### **September 30, 2025 and 2024**

---

*(in thousands of dollars)*

losses) designated to support the clinical, teaching or research efforts of a physician or department as directed by the donor. These contributions are reported as being without donor restrictions, net of related support expenses, when donor restrictions are of a general nature that are inherent in the normal activities of the organization.

The consolidated statements of operations include excess of revenues over expenses. Changes in net assets without donor restrictions, which are excluded from excess of revenues over expenses, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for acquisition of such assets) and change in funded status of defined benefit plans.

#### **Revenues**

To determine the appropriate revenue recognition policy, we first assess whether the transaction is an exchange or nonexchange transaction in accordance with accounting guidance. In general, an exchange transaction consists of an exchange of goods and/or services for commensurate value. Transactions that consist of transferring goods and/or services without receiving commensurate value in return are considered nonexchange transactions.

For exchange transactions, revenue is recognized as goods and/or services are provided and is based on the amount expected to be received in exchange for those goods and/or services. Revenue recognized as exchange transactions include net patient service revenue, premium revenue and other revenue.

Nonexchange transactions include contributions and grants for which the service provider does not receive commensurate value in return for the funding.

#### **Contributions**

Contributions are generally reported as other nonoperating gains in the consolidated statements of operations. Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give are recognized when the conditions are substantially met and totaled \$427,673 and \$403,143 as of September 30, 2025 and 2024, respectively. Contributions are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. Contributions with donor restrictions whose restrictions are met within the same year as received are reported as contributions without donor restrictions in the consolidated statements of operations.

Contributions of long-lived assets with explicit restrictions that specify use of assets and contributions of cash or other assets that must be used to acquire long-lived assets are reported as additions to net assets with donor restrictions if the assets are not placed in service during the year.

#### **Grants**

Grants and contracts normally provide for the recovery of direct and indirect costs, subject to audit. Revenue associated with direct and indirect costs is recognized as direct costs are incurred. The recovery of indirect costs is based on rates for U.S. Government grants and contracts and negotiated rates for other grants and contracts.

#### **Medical Claims and Related Expenses**

The Health Plan contracts with various hospitals, community health centers, primary care and specialty physician practices and other health care providers for the delivery of services to its



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

members and compensates these providers on a capitated, fee-for-service, per diem or diagnosis-related group basis.

The cost of contracted health care services is accrued in the period in which services are provided and include certain estimated amounts. The estimated liability for medical claims and related expenses is actuarially determined based on analysis of historical claims-paid experience, modified for changes in enrollment, inflation and benefit coverage. The liability for medical claims and related expenses represents the anticipated cost of claims incurred but unpaid at the balance sheet date. Estimates for claims expense may be more or less than the amounts ultimately paid when claims are settled. Such changes in estimates are reflected in the current period in the consolidated statements of operations.

In the normal course of business, overpayments are recouped through reductions in future payments made to hospitals and other providers. Such overpayments are the result of, among other things, coordination of benefits and provider claim audits. For the years ended September 30, 2025 and 2024, we recorded a reduction in medical claims expense of \$52,568 and \$59,115, respectively, for such overpayments. As of September 30, 2025 and 2024, respectively, approximately \$1,769 and \$1,767 are recorded as receivables related to such overpayments.

#### **Reinsurance**

Reinsurance premiums are reported as reductions in premium revenue and reinsurance recoveries are reported as reductions in medical claims and related expenses.

#### **Settlements**

The Health Plan contracts with certain providers at negotiated rates based on historical and anticipated experience. This method of reimbursement results in year-end settlements based on actual versus anticipated experience. The settlements are intended to include both reported and unreported incurred claims as of September 30, 2025 and 2024.

In certain instances, base premium revenue is subject to risk adjustment based on demographic factors and health status of covered members. Our estimated net receivable due from the federal government for the risk adjustment program under the Patient Protection and Affordable Care Act (ACA) was \$122,295 and \$79,841 as of September 30, 2025 and 2024, respectively. Similar to the federal program, EOHHS has risk-sharing arrangements, and our estimated net receivable from EOHHS was \$121,071 as of September 30, 2025 and our estimated net payable to EOHHS was \$10,712 as of September 30, 2024.

The ACA requires certain health plans with medical loss ratios (MLR) on fully insured products that fall below required minimum percentages to rebate ratable portions of their premium annually. The Health Plan's management thereby regularly monitors MLR calculations by market type and records the applicable liability and reduction to premium revenue if the MLR falls below the minimum requirements. The Health Plan's estimated payable for MLR rebates as of September 30, 2025 and 2024 was \$5,043 and \$7,936, respectively.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

#### **Premium Deficiency Reserves**

Premium deficiency reserves are assessed and recognized on a product line basis based upon expected premium revenue, medical expense and administrative expense levels, and remaining contractual obligations using historical experience. As of September 30, 2025 and 2024, a premium deficiency reserve of \$7,894 and \$33,254, respectively, is included in accrued medical claims and related expenses in the accompanying consolidated financial statements.

#### **Claims Adjustment Expenses**

Claims adjustment expenses (CAE) are those costs expected to be incurred in connection with the adjustment and recording of health claims. We have recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in medical claims and related expenses in the accompanying consolidated statements of operations. Management believes the amount of the liability for unpaid CAE as of September 30, 2025, is adequate to cover the cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE are reflected in operating results in the period in which the change in estimate is identified.

#### **Reclassification**

Within the accompanying notes certain amounts for 2024 have been presented to conform with the 2025 presentation.

### **3. Operating Revenues**

#### **Net Patient Service Revenue**

Mass General Brigham's providers maintain agreements with CMS under the Medicare program, the Commonwealth under the Medicaid program and various managed care payers that govern payment for services rendered to patients covered by these agreements. The agreements generally provide for per case or per diem rates or payments based on discounted charges for inpatient care and discounted charges or fee schedules for outpatient care. Certain contracts also provide for payments that are contingent upon meeting agreed upon quality and efficiency measures.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

We recognize net patient service revenue for services provided to patients who have third-party payer coverage based on contractual rates for the services rendered. For uninsured patients that do not qualify for charity care, we recognize revenue based on our standard rates (subject to discounts) for services provided. Based on our historical experience, a significant portion of uninsured patients are unable or fail to pay for the services provided. Consequently, we have provided implicit discounts to uninsured patients. These discounts represent the difference between amounts billed to patients and amounts expected to be collected based on historical experience. The following summarizes net patient service revenue, net of contractual adjustments and discounts by significant payer:

	Years Ended September 30,			
	2025		2024	
Net patient service revenue (net of contractual adjustments and discounts)				
Medicare	\$ 3,204,501	22.1%	\$ 2,957,873	22.0%
Medicare managed care	1,313,802	9.1%	1,152,455	8.6%
Medicaid	409,525	2.8%	449,718	3.4%
Medicaid managed care	955,589	6.6%	835,802	6.2%
Massachusetts managed care organizations	4,954,040	34.2%	4,710,345	35.0%
Other commercial	3,287,547	22.7%	2,989,867	22.2%
All others	355,060	2.5%	343,896	2.6%
Total all payers	\$ 14,480,064	100.0%	\$ 13,439,956	100.0%

Net patient service revenue includes estimated retroactive revenue adjustments due to future audits, reviews and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews and investigations. Contracts, laws and regulations governing the Medicare, Medicaid and charity care programs and managed care payer arrangements are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. A portion of the accrual for settlements with third-party payers has been classified as long-term because such amounts, by their nature or by virtue of regulation or legislation, will not be paid within one year.

Third-party payers (accrual) receivable consists of the following:

		September 30,	
		2025	2024
<b>Current portion</b>			
Receivable for settlements with third-party payers	Other current assets	\$ 167,811	\$ 153,064
Payable for settlements with third-party payers	Accounts payable and accrued expenses	(92,740)	(115,461)
		<u>75,071</u>	<u>37,603</u>
<b>Long-term portion</b>			
Receivable for settlements with third-party payers	Other assets	53,353	26,956
Payable for settlements with third-party payers	Accrued other	(21,124)	(10,141)
		<u>32,229</u>	<u>16,815</u>
Third-party payers receivable, net		<u>\$ 107,300</u>	<u>\$ 54,418</u>



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

We recognize changes in third-party payer settlements and other estimates in the year of the change in estimate. For the years ended September 30, 2025 and 2024, adjustments to prior year estimates resulted in an increase to net patient service revenue of \$45,711 and \$120,290, respectively. Subsequent changes to estimated discounts are generally recorded as adjustments to net patient service revenue in the period of change.

We provide either full or partial charity care to patients who cannot afford to pay for their medical services based on income and family size. Charity care is generally available to qualifying patients for medically necessary services. We report certain bad debts related to emergency services as charity care. As there is no expectation of collection, there is no net patient service revenue recorded related to charity care.

#### Premium Revenue

Premiums are due monthly and are recorded as earned during the period in which members are eligible to receive services. Premiums received prior to the first day of the coverage period are recorded as unearned premiums in accounts payable and accrued expenses.

#### Research and Nonresearch Sundry Revenue

Research and nonresearch sundry revenue is recognized as either an exchange or nonexchange transaction, depending on the contract type. The following table sets forth total research and nonresearch sundry revenue received by funding source:

	Years Ended September 30,			
	2025		2024	
National Institute of Health and other federal agencies	\$ 1,310,802	43.1%	\$ 1,256,379	43.3%
Federal subcontracts	286,763	9.4%	289,876	10.0%
Industry/corporate	224,282	7.4%	233,689	8.1%
Foundations/nonprofits and other sponsors	1,218,596	40.1%	1,120,806	38.6%
Total research and nonresearch sundry revenue	<u>\$ 3,040,443</u>	<u>100.0%</u>	<u>\$ 2,900,750</u>	<u>100.0%</u>

#### Other Revenue

Other revenue includes all other operating revenue sources, the most significant being the following:

	Years Ended September 30,	
	2025	2024
Specialty and retail pharmacy operations	\$ 1,892,341	\$ 1,211,649
Contract services	192,451	193,706
Ancillary revenue	118,089	121,011
Tuition	70,067	66,570
Blood factor revenue	76,704	57,482
International contracts	11,004	16,458
Income (loss) on intellectual property investments and royalties	(6,988)	40,713
Investment income	13,795	13,482
Other	382,398	318,533
Total other revenue	<u>\$ 2,749,861</u>	<u>\$ 2,039,604</u>

Ancillary revenue includes cafeteria and parking revenue.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

#### COVID-19 Economic Support

We received Provider Relief Funds (PRF) in 2020 and 2021 that were used to prevent, prepare for and respond to COVID-19. As of September 30, 2025 and 2024, we have deferred \$32,487 and \$86,487, respectively, of PRF received.

We submitted applications to the Federal Emergency Management Agency (FEMA) for the reimbursement of COVID-19 expenses and recognized grant revenue totaling \$0 and \$19,699, in 2025 and 2024, respectively, as other operating revenue in the consolidated statements of operations. As of September 30, 2025 and 2024, we have deferred \$53,367 and \$54,792, respectively, of FEMA payments received.

#### 4. Liquidity and Availability

Cash and investments are managed centrally under policies developed by the Investment Committee of the Company's Board of Directors. Wherever possible, funds are commingled and are assigned to one of three investment pools (the Money Market Pool, the Aggregate Bond Pool and the Long Term Pool, collectively, the Pools) which have been structured to provide a range of investment objectives, risk profiles and rates of return appropriate for our assets. Funds are allocated among the Pools based on expected liquidity needs as determined by multi-year financial plans, restrictions and management judgment.

The tiered time horizon structure of the Pools is designed to meet anticipated and contingent liquidity needs. The following tables set forth the periods within which funds are available to meet liquidity needs and based on redemption provisions with investment managers, the specific Pools from which such funds would be drawn as of:

Investment Pool	September 30, 2025						Total
	Same Day	1 Week	1 Month	3 Months	1 Year	> 1 Year	
Money Market Pool	\$ 426,548	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 426,548
Aggregate Bond Pool	419,423	3,044	-	-	-	-	422,467
Long Term Pool	1,162,871	419,308	2,077,049	4,545,516	1,440,366	7,764,339	17,409,449
Total	\$ 2,008,842	\$ 422,352	\$ 2,077,049	\$ 4,545,516	\$ 1,440,366	\$ 7,764,339	\$ 18,258,464
Cumulative total	\$ 2,008,842	\$ 2,431,194	\$ 4,508,243	\$ 9,053,759	\$ 10,494,125	\$ 18,258,464	

Investment Pool	September 30, 2024						Total
	Same Day	1 Week	1 Month	3 Months	1 Year	> 1 Year	
Money Market Pool	\$ 2,314	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 2,314
Aggregate Bond Pool	404,374	3,311	-	-	-	-	407,685
Long Term Pool	851,883	807,904	2,285,293	4,204,208	1,425,925	6,299,312	15,874,525
Total	\$ 1,258,571	\$ 811,215	\$ 2,285,293	\$ 4,204,208	\$ 1,425,925	\$ 6,299,312	\$ 16,284,524
Cumulative total	\$ 1,258,571	\$ 2,069,786	\$ 4,355,079	\$ 8,559,287	\$ 9,985,212	\$ 16,284,524	

As of September 30, 2025 and 2024, we had cash and equivalents not included in the Pools of \$103,100 and \$105,823, respectively. As of September 30, 2025 and 2024, we had net patient accounts receivable of \$1,774,269 and \$1,731,496, respectively, that would be available for general expenditures within one year of the balance sheet dates.

#### 5. Investments and Investments Limited as to Use

Investments are either invested in the Pools or separately managed. Substantially all affiliates participate in the Pools. Their respective ownership interests are tracked and updated monthly and



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

(in thousands of dollars)

are accounted for using the fair value method. Income (including realized gains and losses) from the Pools is allocated to each participant on a monthly basis based on its proportionate interest in the Pools.

Oversight of the management of the investable assets, including the Pools and pension assets, is provided by the Investment Committee of the Company's Board of Directors which seeks to achieve incremental returns by external manager selection and asset allocation (increasing/decreasing allocations within allowable ranges based on current and projected valuations). The Committee is supported by a professional staff of the Company's employees and an external pension actuarial consultant.

The Pools invest in a variety of assets which include private partnerships whose assets include equity, fixed income and other investments. The Pools have unfunded commitments to such private partnerships as follows:

	<b>September 30,</b>	
	<b>2025</b>	<b>2024</b>
Private equity	\$ 1,644,081	\$ 1,676,110
Private energy	89,788	89,816
Private real estate	106,592	102,876
Timber and agriculture	1,587	1,524
Private alternatives and hedge funds	291,708	195,972
	<u>\$ 2,133,756</u>	<u>\$ 2,066,298</u>

The unfunded commitments will be drawn down by the various general partners of such partnerships over the next several years. The maximum annual drawdown is expected to be 3% to 5% of investments and investments limited as to use, however the actual amount may vary.

#### Short-term Investments in Investment Pools

Within the Aggregate Bond Pool and the Long Term Pool, there are assets that meet the definition of short-term investments. These short-term investments are considered part of the Aggregate Bond Pool and the Long Term Pool and are not included in cash equivalents on the consolidated balance sheets. Accordingly, transactions within the Aggregate Bond Pool and the Long Term Pool that result in the purchase of investments or result in proceeds from the sales of investments are excluded from the statements of cash flows purchases of investments and proceeds from the sales of investments. Within the Aggregate Bond Pool, purchases of investments and proceeds from the sales of investments not included in the statements of cash flows were \$161,119 and \$128,440 for the year ended September 30, 2025, and \$247,387 and \$187,061 for the year ended September 30, 2024, respectively. Within the Long Term Pool, purchases of investments and proceeds from the sales of investments not included in the statements of cash flows were \$2,767,455 and \$3,216,543 for the year ended September 30, 2025, and \$1,632,747 and \$1,966,849 for the year ended September 30, 2024, respectively.



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(in thousands of dollars)

Investments limited as to use consist of the following:

	<b>September 30, 2025</b>		<b>September 30, 2024</b>	
	<b>Current Portion</b>	<b>Long-Term Portion</b>	<b>Current Portion</b>	<b>Long-Term Portion</b>
<b>Internally designated funds</b>				
Reserved for capital expenditures	\$ 1,289,839	\$ -	\$ 1,244,666	\$ -
Unexpended research and nonresearch sundry gifts	-	5,926,993	-	5,131,842
Deferred compensation	-	927,390	-	798,484
Other	1,603,223	490,846	2,030,166	461,821
	<u>2,893,062</u>	<u>7,345,229</u>	<u>3,274,832</u>	<u>6,392,147</u>
<b>Externally limited funds</b>				
Unexpended funds on research	469,114	-	369,851	-
Contributions held for others	1,540	-	1,519	-
Professional liability trust fund	-	58,887	-	50,886
Held by trustees under debt and other agreements	424	-	5,525	-
	<u>471,078</u>	<u>58,887</u>	<u>376,895</u>	<u>50,886</u>
	<u>\$ 3,364,140</u>	<u>\$ 7,404,116</u>	<u>\$ 3,651,727</u>	<u>\$ 6,443,033</u>

Investment activity included in excess of revenues over expenses consists of the following:

	<b>Years Ended September 30,</b>	
	<b>2025</b>	<b>2024</b>
Investment income included in operations and reported in other revenue	\$ 13,795	\$ 13,482
Investment income included in nonoperating gains and reported in		
Income from investments		
Investment income and realized gains on investments	646,313	327,105
Unrealized change in investments	1,104,819	1,622,965
Research and nonresearch sundry gifts net of spending	<u>419,998</u>	<u>291,979</u>
Total investment activity included in excess of revenues over expenses	<u>\$ 2,184,925</u>	<u>\$ 2,255,531</u>

**6. Fair Value Measurements**

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (also referred to as exit price). Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. In determining fair value, the use of various valuation approaches, including market, income and cost approaches, is permitted.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

#### **Fair Value Hierarchy**

A fair value hierarchy has been established based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the reporting entity's assumptions about the inputs market participants would use. The fair value hierarchy requires the reporting entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. In addition, for hierarchy classification purposes, the reporting entity should not look through the form of an investment to the nature of the underlying securities held by an investee.

The hierarchy is described below:

- Level 1    Valuations using quoted prices in active markets for identical assets or liabilities. Valuations of these products do not require a significant degree of judgment. Level 1 assets and liabilities primarily include debt and equity securities that are traded in an active exchange market.
- Level 2    Valuations using observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; broker or dealer quotations; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities primarily include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities and derivative contracts whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.
- Level 3    Valuations using unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the reporting entity's assumptions about the assumptions market participants would use as well as those requiring significant management judgment.

#### **Valuation Techniques**

Pooled investments, separately invested short-term investments and debt and equity securities are classified within Level 1 or Level 2 of the fair value hierarchy as they are valued using quoted market prices, broker or dealer quotations, or other observable pricing sources. Certain types of investments are classified within Level 3 of the fair value hierarchy because they have little or no market activity and therefore have little or no observable inputs with which to measure fair value.

The valuation of interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

The following tables summarize financial assets and liabilities measured at fair value on a recurring basis as of:

	September 30, 2025				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	Total
<b>Assets</b>					
Pooled investments					
Short-term investments	\$ 699,500	\$ -	\$ -	\$ -	\$ 699,500
Separately managed investments	1,386,099	554,983	-	-	1,941,082
Mutual funds	3,044	-	-	-	3,044
Private partnerships, commingled funds and other	-	-	-	15,614,838	15,614,838
	<u>2,088,643</u>	<u>554,983</u>	<u>-</u>	<u>15,614,838</u>	<u>18,258,464</u>
Separately invested					
Short-term investments	31,652	-	-	-	31,652
Equities	21,643	-	-	-	21,643
Mutual funds	927,554	83,603	-	-	1,011,157
Private partnerships, commingled funds and other	-	-	-	199,788	199,788
Beneficial interests in perpetual assets	-	-	58,614	-	58,614
	<u>980,849</u>	<u>83,603</u>	<u>58,614</u>	<u>199,788</u>	<u>1,322,854</u>
	<u>\$ 3,069,492</u>	<u>\$ 638,586</u>	<u>\$ 58,614</u>	<u>\$ 15,814,626</u>	<u>\$ 19,581,318</u>
<b>Interest rate swaps</b>					
Assets		\$ 48,376			\$ 48,376
Liabilities		<u>(85,312)</u>			<u>(85,312)</u>
Net interest rate swaps		\$ (36,936)			\$ (36,936)



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(in thousands of dollars)

	September 30, 2024				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	Total
<b>Assets</b>					
Pooled investments					
Short-term investments	\$ 756,519	\$ -	\$ -	\$ -	\$ 756,519
Separately managed investments	1,199,960	119,041	-	-	1,319,001
Mutual funds	3,310	-	-	-	3,310
Private partnerships, commingled funds and other	-	-	-	14,205,694	14,205,694
	<u>1,959,789</u>	<u>119,041</u>	<u>-</u>	<u>14,205,694</u>	<u>16,284,524</u>
Separately invested					
Short-term investments	31,248	-	-	-	31,248
Equities	41,395	-	-	-	41,395
Mutual funds	838,661	68,469	-	-	907,130
Private partnerships, commingled funds and other	-	-	-	223,540	223,540
Beneficial interests in perpetual assets	-	-	56,033	-	56,033
	<u>911,304</u>	<u>68,469</u>	<u>56,033</u>	<u>223,540</u>	<u>1,259,346</u>
	<u>\$ 2,871,093</u>	<u>\$ 187,510</u>	<u>\$ 56,033</u>	<u>\$ 14,429,234</u>	<u>\$ 17,543,870</u>
<b>Interest rate swaps</b>					
Assets		\$ 43,855			\$ 43,855
Liabilities		(139,170)			(139,170)
Net interest rate swaps		<u>\$ (95,315)</u>			<u>\$ (95,315)</u>



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(in thousands of dollars)

**7. Pledges and Contributions Receivable**

Pledges receivables represent unconditional promises to give and are net of allowances for uncollectible amounts. Pledges are recorded at the present value of their estimated future cash flows. Pledges collectible within one year are classified as other current assets, net of allowances, and total \$199,430 and \$221,076 as of September 30, 2025 and 2024, respectively. Pledges collectible in one year or greater are classified as other assets. Estimated cash flows due after one year are discounted using published treasury bond and note yields that are commensurate with estimated collection risks. The blended discount rate was 3.7% and 3.6% for 2025 and 2024, respectively. Pledges are expected to be collected as follows:

	<b>September 30,</b>	
	<b>2025</b>	<b>2024</b>
Amounts due		
Within one year	\$ 220,743	\$ 240,290
In one to five years	332,654	330,412
In more than five years	173,052	112,107
Total pledges receivable	726,449	682,809
Less: Unamortized discount	58,399	45,623
	668,050	637,186
Less: Allowance for uncollectibles	33,839	27,441
Net pledges receivable	634,211	609,745
Contributions receivable from trusts	43,721	51,932
	<u>\$ 677,932</u>	<u>\$ 661,677</u>

**8. Property and Equipment**

Property and equipment consists of the following:

	<b>September 30,</b>	
	<b>2025</b>	<b>2024</b>
Land and land improvements	\$ 355,497	\$ 355,891
Buildings and building improvements	10,879,593	10,244,802
Equipment	3,346,428	2,961,248
Construction in progress	1,646,920	1,545,009
Finance right-of-use lease assets	118,665	108,623
	16,347,103	15,215,573
Less: Accumulated depreciation	8,517,223	7,743,833
Property and equipment, net	<u>\$ 7,829,880</u>	<u>\$ 7,471,740</u>



# **Mass General Brigham Incorporated and Affiliates**

## **Notes to Consolidated Financial Statements**

### **September 30, 2025 and 2024**

---

*(in thousands of dollars)*

Depreciation expense for the years ended September 30, 2025 and 2024 was \$791,200 and \$777,893, respectively. Interest costs, net of interest earned, aggregating \$40,266 and \$12,322 were capitalized in 2025 and 2024, respectively.

For the years ended September 30, 2025 and 2024, fully depreciated assets with an original cost of \$21,863 and \$393,357, respectively, were written off.

#### **9. Level of Capital and Surplus**

Risk-based capital (RBC) is a methodology adopted by the National Association of Insurance Commissioners for determining the minimum level of capital and surplus deemed necessary for an insurer based upon the types of assets held and business written. The Company has guaranteed to the Massachusetts Division of Insurance (DOI) (the RBC Guaranty) to maintain the Health Plan's capital and surplus at a specified minimum level, measured quarterly in accordance with an RBC methodology permitted by DOI. The RBC Guaranty may be enforced by the DOI. The Company provided capital to the Health Plan of \$75,000 and \$0 in 2025 and 2024, respectively. Mass General Brigham Health Plan, Inc.'s current contract with EOHHS requires it to maintain a minimum net worth as defined under GAAP and/or financial insolvency insurance in an amount equal to the Minimum Net Worth calculation as defined in Massachusetts General Law 176G, Section 25. At December 31, 2024 and 2023 (Mass General Brigham Health Plan, Inc.'s statutory year end), the minimum net worth requirement, as determined in accordance with EOHHS guidelines, was \$71,846 and \$69,306, respectively. Mass General Brigham Health Plan, Inc.'s GAAP net worth was \$205,175 and \$212,686 at December 31, 2024 and 2023, respectively, and thus exceeded the EOHHS requirements by \$133,329 and \$143,380, respectively.

#### **10. Accrued Medical Claims and Related Expenses**

Accrued medical claims and related expenses include estimates of expected trends in claims severity, frequency, and other factors, which could vary as the claims are ultimately settled. In establishing this reserve, the Company has utilized the services of actuaries to review the reasonableness of the reserves based upon the historical experience of the Company.



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

---

(in thousands of dollars)

The changes in accrued medical claims and related expenses for the years ended September 30, 2025 and 2024 are as follows:

	2025	2024
<b>Balance at beginning of year</b>	\$ 258,520	\$ 192,435
Less		
Premium deficiency reserve	(33,254)	(24,071)
Accrual for claims adjustment expenses	(4,204)	(2,962)
Accrued medical payables - other	(30,414)	(19,646)
Plus: Settlements payable, net	164,178	135,763
<b>Net balance at beginning of year</b>	<u>354,826</u>	<u>281,519</u>
Incurred related to		
Current year	1,802,086	1,487,755
Prior years	17,387	17,283
Total incurred	<u>1,819,473</u>	<u>1,505,038</u>
Paid related to		
Current year	1,631,586	1,270,729
Prior years	211,604	161,002
Total paid	<u>1,843,190</u>	<u>1,431,731</u>
<b>Net balance at end of year</b>	331,109	354,826
Plus		
Premium deficiency reserve	7,894	33,254
Accrual for claims adjustment expenses	3,804	4,204
Accrued medical payables - other	61,868	30,414
Less: Settlements payable, net	<u>(189,094)</u>	<u>(164,178)</u>
<b>Balance at end of year</b>	<u>\$ 215,581</u>	<u>\$ 258,520</u>

As a result of changes in estimates of insured events in prior years and recoveries, the liability on claims existing on October 1, 2024 and 2023, increased \$17,387 and \$17,283, respectively, for the years ended September 30, 2025 and 2024, respectively. Changes of this nature occur as the result of claim settlements and recoveries during the current year and as additional information is received regarding individual claims, causing changes from the original estimates of the cost of these claims. Ongoing analysis of the recent loss development trends is also taken into account in evaluating the overall adequacy of the reserves. The increase in incurred claims related to prior years is primarily the result of higher than anticipated utilization of health care services across the industry and for the Company.

Medical claims and related expenses in the accompanying consolidated statements of operations include other nonclaims related costs. These nonclaims related expenses were for statewide assessments, totaling approximately \$87,892 and \$14,962 for the years ended September 30, 2025 and 2024, respectively.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

#### 11. Long-Term Obligations

Mass General Brigham's long-term obligations consist of the following:

	Final Maturity	September 30,	
		2025	2024
Massachusetts Health and Educational Facilities Authority Revenue Bonds			
Series 1997 P*, variable interest rate of 2.55% and 2.99%	2027	\$ 60,000	\$ 90,000
Series 2005 F*, variable interest rate of 2.99% and 3.03%	2040	220,100	222,250
Series 2007 G*, variable interest rate of 3.00% and 3.00%	2042	75,000	75,000
Series 2008 H*, variable interest rate of 2.75% and 3.44%	2042	150,370	153,675
Massachusetts Development Finance Agency (Agency) Revenue Bonds			
Series 2011 K*, variable interest rate of 2.55% and 3.03%	2046	100,000	100,000
Series 2014 M*, average fixed interest rate of 3.63%	2026	560	1,835
Series 2014 N*, variable interest rate of 4.07% and 4.86%	2044	120,100	122,250
Series 2015 O*, average fixed interest rate of 4.34%	2045	149,545	159,870
Series 2016 Q*, average fixed interest rate of 4.81%	2047	373,665	384,395
Series 2017 S*, average fixed interest rate of 4.47%	2047	573,785	652,785
Series 2019 T*, variable interest rate of 3.49% and 3.72%	2049	80,000	108,250
Series 2020 A*, average fixed interest rate of 4.80%	2050	252,795	268,130
Series 2022 B*, variable interest rate of 3.85% and 4.67%	2052	100,230	100,230
Series 2023 C, variable interest rate of 4.03% and 4.78%	2038	69,870	69,870
Series 2024 D, average fixed interest rate of 5.00%	2054	309,185	309,185
Series 2024 E*, variable interest rate of 2.48% and 3.50%	2052	150,000	150,000
New Hampshire Health and Education Facilities Authority Revenue Bonds			
Series 2017, average fixed interest rate of 5.00%	2041	80,875	84,445
Mass General Brigham Taxable Debt			
Series 2007 Bonds, fixed interest rate of 6.26%	2037	100,000	100,000
2012 Senior Notes, fixed interest rate of 4.11%	2052	400,000	400,000
2014 Senior Notes, fixed interest rate of 4.73%	2044	150,000	150,000
Series 2015 Bonds, fixed interest rate of 4.12%	2055	300,000	300,000
2016 Senior Notes, fixed interest rate of 3.89%	2046	225,000	225,000
Series 2017 Bonds, fixed interest rate of 3.77%	2048	303,644	303,644
2018 Senior Notes, fixed interest rate of 4.60%	2049	400,000	400,000
Series 2020 Bonds, average fixed interest rate of 3.29%	2060	1,017,135	1,017,135
Series B-1 Commercial Paper Notes, variable interest rate of 4.33% and n/a	2025	61,935	-
Other obligations		1,284	1,880
Total long-term obligations, par value		5,825,078	5,949,829
Net unamortized bond premiums		246,636	265,952
Deferred financing costs		(23,499)	(24,953)
Total long-term obligations, net		6,048,215	6,190,828
Less			
Current portion		448,435	353,249
		<u>\$ 5,599,780</u>	<u>\$ 5,837,579</u>

\* Denotes series is issued in multiple subseries

Variable interest rates are presented at September 30, 2025 and 2024, respectively



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

---

(in thousands of dollars)

Scheduled maturities of long-term obligations (including the impact of net unamortized bond premiums and deferred financing costs) during the next five years and thereafter and other amounts classified as current liabilities, are as follows:

	<b>Scheduled Maturities</b>	<b>Bonds Supported by Self Liquidity</b>	<b>Bonds Supported by Bank Facilities</b>	<b>Total</b>
2026	\$ 155,565	\$ 230,370	\$ 62,500	\$ 448,435
2027	101,148	-	-	101,148
2028	89,496	-	-	89,496
2029	91,785	-	-	91,785
2030	102,495	-	-	102,495
Thereafter	5,214,856	-	-	5,214,856
	<u>\$ 5,755,345</u>	<u>\$ 230,370</u>	<u>\$ 62,500</u>	<u>\$ 6,048,215</u>

The scheduled maturities represent annual payments as required under debt repayment schedules. The current portion of long-term obligations includes the payments scheduled to be made in 2026, bonds supported by self-liquidity that can be tendered prior to September 30, 2026, and bonds supported by bank facilities with financial institutions (standby bond purchase agreements or letters of credit) that expire prior to September 30, 2026 or have potential principal amortization under bank facilities' term out provisions due during 2026. The bonds supported by self-liquidity provide the bondholder with an option to tender the bonds to the Company. Accordingly, these bonds are classified as a current liability. The bonds supported by bank facilities provide the bondholder with an option to tender the bonds to the liquidity provider. Generally accepted accounting principles require bonds backed by bank facilities expiring within one year of the balance sheet date as well as potential principal amortization under bank facilities' term out provisions due within one year of the balance sheet date to be classified as a current liability.

If bonds supported by bank facilities cannot be remarketed, the repayment terms of those bank facilities would result in repayments of \$35,000 in 2026, \$157,533 in 2027, \$135,033 in 2028, \$52,533 in 2029, and \$0 thereafter. If the bonds supported by self-liquidity cannot be remarketed, the bonds would be tendered to the Company on their respective earliest tender dates, which differ from scheduled maturity dates, and would result in payments of \$230,370 in 2026, \$0 in 2027, \$0 in 2028, \$0 in 2029, \$76,020 in 2030 and \$163,495 thereafter.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

(in thousands of dollars)

Scheduled payments of long-term debt (excluding the impact of net unamortized bond premiums and deferred financing costs) for each of the next five years, assuming bonds backed by bank facilities are remarketed and the standby purchase agreements are renewed and bonds supported by self-liquidity are remarketed, are as follows:

2026	\$ 93,630
2027	101,148
2028	99,031
2029	100,945
2030	111,820
Thereafter	<u>5,318,504</u>
	<u>\$ 5,825,078</u>

Interest expense paid during the years ended September 30, 2025 and 2024 was \$249,466 and \$247,287, respectively.

In January 2024, we issued \$309,185 of Mass General Brigham Series 2024 D Revenue Bonds, plus bond premium of \$34,049. The bond proceeds, net of issuance costs of \$2,594, were used to refund Partners HealthCare System Series 2017 S-4 Bonds (\$69,481) and to finance certain capital projects (\$271,158).

In January 2024, we issued \$150,000 of Mass General Brigham Series 2024 E Revenue Bonds. The bond proceeds, net of issuance costs of \$1,659, were used to refund Taxable Commercial Paper Notes (\$50,000) that refinanced, on an interim basis, Partners HealthCare System Series 2016 R-2 Revenue Bonds, and to finance certain capital projects (\$98,341).

In December 2023, we issued \$69,870 of Mass General Brigham Series 2023 C Revenue Bonds. The bond proceeds were used to refund Taxable Commercial Paper Notes that refinanced, on an interim basis, Partners HealthCare System Series 2017 S-3 Revenue Bonds.

Mass General Brigham bonds are general obligations of the Company supported by guarantees from Brigham, Inc., The Brigham and Women's Hospital, Inc., The Massachusetts General Hospital and The General Hospital Corporation (the General) which may be suspended under certain conditions.

Our debt agreements contain certain covenants, including a minimum debt service coverage ratio and limitations on additional indebtedness and asset transfers.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

#### **Lines of Credit**

The Company maintains two lines of credit aggregating \$375,000 that provide access to same day funds. Advances under the lines of credit bear a variable rate of interest based on the Secured Overnight Financing Rate (SOFR). As of September 30, 2025 and 2024, there were no amounts outstanding under the lines of credit. The \$250,000 line of credit expires in July 2028. The \$125,000 line of credit expires in July 2027.

#### **Taxable Commercial Paper**

The Company maintains a \$500,000 Taxable Commercial Paper (CP) program. As of September 30, 2025 and 2024, there was \$61,935 and \$0, respectively, outstanding under the CP program.

## **12. Derivatives**

#### **Interest Rate Swaps**

We utilize swap contracts to lock in long-term synthetic fixed rates and manage fluctuations in cash flows resulting from interest rate risk on certain of our variable rate bonds. These bonds expose us to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit this variability. To meet this objective and to take advantage of low interest rates, we have entered into various swap contracts involving the exchange of fixed rate payments by us for variable rate payments from several counterparties. These variable rate payments are currently based on a percentage of SOFR (based on compound average of daily SOFR in arrears) plus a spread.

By using swap contracts to manage the risk of changes in interest rates, we expose ourselves to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the swap contracts. When the fair value of a swap contract is positive, the counterparty has a liability to us, which creates credit risk. We minimize our credit risk by entering into swap contracts with several counterparties and requiring the counterparty to post collateral for our benefit based on the credit rating of the counterparty and the fair value of the swap contract. Conversely, when the fair value of a swap contract is negative, we have a liability to the counterparty and, therefore, we do not have credit risk. Under certain circumstances, we may be required to post collateral for the benefit of the counterparty. Market risk is the adverse effect on the value of a financial instrument that results from a change in interest rates. The market risk associated with interest rate changes is managed by establishing and monitoring parameters that limit the types and degree of market risk that we may undertake.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

(in thousands of dollars)

In 2025, we terminated various swap contracts with a total notional amount of \$243,750 and received \$25,788 net proceeds. The following is a summary of the outstanding positions under our swap contracts as of September 30, 2025:

Effective Date	Notional Amount	Maturity	Rate Paid	Rate Received
5/1/03	\$ 44,081	7/1/35	4.45%	67% 1M SOFR + 0.0767%
10/15/03	7,360	1/1/31	3.85%	70% 1M SOFR + 0.08014%
7/1/05	150,000	7/1/50	3.09%	67% 1M SOFR + 0.0767%
7/1/07	150,000	7/1/52	2.96%	67% 1M SOFR + 0.0809%
7/1/09	100,000	7/1/50	3.58%	67% 1M SOFR + 0.0767%
7/1/11	100,000	7/1/50	3.66%	67% 1M SOFR + 0.0767%
7/1/13	100,000	7/1/48	3.80%	67% 1M SOFR + 0.0767%
7/1/15	50,000	7/1/50	3.80%	67% 1M SOFR + 0.0767%
4/1/16	100,000	7/1/52	3.76%	67% 1M SOFR + 0.0767%
7/1/17	50,000	7/1/52	3.74%	67% 1M SOFR + 0.083%
7/1/27	100,000	7/1/57	1.79%	67% 1M SOFR + 0.07985%
7/1/29	50,000	7/1/49	1.41%	67% 1M SOFR + 0.0767%
7/1/29	50,000	7/1/54	1.51%	67% 1M SOFR + 0.0767%
7/1/31	50,000	7/1/55	1.50%	67% 1M SOFR + 0.083%
7/1/31	50,000	7/1/56	1.55%	67% 1M SOFR + 0.0767%
7/1/33	50,000	7/1/51	1.03%	67% 1M SOFR + 0.0767%
	<u>\$ 1,201,441</u>			

Our swap contracts contain provisions that require collateral to be posted if the fair value of the swap exceeds certain thresholds. The collateral thresholds reflect the current credit ratings issued by major credit rating agencies on our and the counterparty's debt. Declines in our or the counterparty's credit ratings would result in lower collateral thresholds and, consequently, the potential for additional collateral postings by us or the counterparty. As of September 30, 2025, we posted collateral of \$0 and held collateral of \$11,900 and as of September 30, 2024, we posted collateral of \$5,320 and held collateral of \$850. We have established procedures to ensure that liquidity and securities are available to meet collateral posting requirements.

Upon the occurrence of certain events of default or termination events identified in the swap contracts, either the Company or the counterparty could terminate the contracts in accordance with their respective terms. Termination results in the payment of a termination amount by one party that attempts to compensate the other party for its economic losses. If interest rates at the time of termination are lower than those specified in the swap contract, we would make a payment to the counterparty. Conversely, if interest rates at such time are higher, the counterparty would make a payment to us.

### 13. Leases

We lease property and equipment under both finance and operating lease agreements. We recognize leases with a term greater than twelve months on the balance sheets.



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(in thousands of dollars)

Some lease agreements require us to pay variable costs including property taxes, insurance, maintenance and repairs. Variable costs are excluded from the right-of-use asset and liability. Lease and nonlease components of agreements are not separated. Some leases contain rental escalation clauses and renewal options that are included in lease payment calculations when appropriate. The estimated incremental borrowing rate is used to discount the lease payment amounts.

The components of lease expense consist of the following:

	<b>Year Ended September 30, 2025</b>		
	<b>Supplies and Other Expenses</b>	<b>Research and Nonresearch Sundry Gifts, Net of Expenses</b>	<b>Total</b>
Operating lease expense	\$ 206,602	\$ 2,064	\$ 208,666
Short-term lease expense	13,379	181	13,560
Variable lease expense	77,139	1,416	78,555
Finance lease expense			
Amortization of leased assets	17,158	179	17,337
Interest on lease liabilities	3,705	28	3,733
Total lease expense	<u>\$ 317,983</u>	<u>\$ 3,868</u>	<u>\$ 321,851</u>
	<b>Year Ended September 30, 2024</b>		
	<b>Supplies and Other Expenses</b>	<b>Research and Nonresearch Sundry Gifts, Net of Expenses</b>	<b>Total</b>
Operating lease expense	\$ 218,534	\$ 2,217	\$ 220,751
Short-term lease expense	14,059	251	14,310
Variable lease expense	78,914	968	79,882
Finance lease expense			
Amortization of leased assets	16,088	174	16,262
Interest on lease liabilities	3,633	16	3,649
Total lease expense	<u>\$ 331,228</u>	<u>\$ 3,626</u>	<u>\$ 334,854</u>



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

---

(in thousands of dollars)

Lease related assets and liabilities are as follows:

		<b>September 30,</b>	
		<b>2025</b>	<b>2024</b>
	<b>Balance Sheet Classification</b>		
Operating lease assets	Right-of-use operating lease assets	\$ 801,815	\$ 920,702
Finance lease assets	Property and equipment, net	70,368	62,646
Total lease assets		<u>\$ 872,183</u>	<u>\$ 983,348</u>
Current operating lease liability	Current portion of operating lease obligations	\$ 155,897	\$ 203,879
Current finance lease liability	Accounts payable and accrued expenses	14,355	16,808
Noncurrent operating lease liability	Operating lease obligation, less current portion	545,738	598,065
Noncurrent finance lease liability	Accrued other	62,579	68,333
Total lease liabilities		<u>\$ 778,569</u>	<u>\$ 887,085</u>

Supplemental cash flow and other information related to leases are as follows:

		<b>Years Ended September 30,</b>	
		<b>2025</b>	<b>2024</b>
<b>Cash paid for amounts included in the measurement of lease liabilities</b>			
Operating cash flow for operating leases	\$	212,888	\$ 213,333
Operating cash flow for finance leases		3,908	3,453
Financing cash flows for finance leases		16,698	14,249
<b>Weighted-average remaining term (years)</b>			
Operating leases		6.7	12.0
Finance leases		21.0	15.0
<b>Weighted-average discount rate</b>			
Operating leases		4.07 %	4.07 %
Finance leases		4.07 %	4.07 %



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

---

(in thousands of dollars)

Commitments related to noncancelable operating and finance leases for each of the next five years and thereafter are as follows:

	Operating Leases	Finance Leases
2026	\$ 186,072	\$ 16,148
2027	153,772	9,298
2028	130,837	6,672
2029	80,205	4,211
2030	52,441	3,616
Thereafter	171,595	111,303
Total minimum future payments	774,922	151,248
Less: Amount representing interest	(73,287)	(74,314)
Present value of minimum future payments	701,635	76,934
Less: Current portion	(155,897)	(14,355)
Long-term lease obligations	\$ 545,738	\$ 62,579

We are also a lessor and sublessor of real estate under operating leases. Lease income for the years ended September 30, 2025 and 2024 was \$7,118 and \$15,488, respectively, and is included in other revenue in the consolidated statements of operations. Some of these leases include expenses such as utilities and maintenance costs in rent charges, however, this variable lease income is not considered material. We do not separate lease and nonlease components by class of underlying asset for all asset classes. The underlying real estate assets are included in property and equipment, net in the consolidated balance sheets.

The future undiscounted cash flows to be received from these leases for each of the next five years and thereafter is as follows:

2026	\$ 10,514
2027	8,263
2028	7,190
2029	6,499
2030	5,825
Thereafter	51,158
	\$ 89,449

#### **14. Construction Projects**

The General is constructing a new clinical building, the Phillip and Susan Ragon Building, that will occupy approximately one million square feet and will contain 482 private medical/surgical and intensive care unit beds, exam and infusion bays associated with a relocated and expanded outpatient oncology service, hybrid and conventional cardiovascular operating rooms, and associated imaging modalities as well as below-grade parking. As of September 30, 2025, accumulated costs incurred related to the new clinical building are approximately \$1,064,024 with



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

approximately \$580,447 in outstanding construction project contracts. The total cost of the project is expected to be approximately \$3,311,000 with occupancy scheduled for 2027 for Phase 1 and 2030 for Phase 2.

#### 15. Pension and Postretirement Health Care Benefit Plans

Substantially all Mass General Brigham employees are covered under noncontributory defined benefit pension plans and various defined contribution pension plans. In addition, certain affiliates provide subsidized health care benefits for retired employees on a self-insured basis, with the benefit obligation being partially funded. These retiree health care benefits are administered through a third-party administrator and are accounted for on the accrual basis, which includes an estimate of future payments for claims incurred.

Total net periodic pension and postretirement costs for Mass General Brigham plans consists of the following:

	<b>Years Ended September 30,</b>	
	<b>2025</b>	<b>2024</b>
Defined benefit plans	\$ 188,907	\$ 106,335
Defined contribution plans	220,993	213,275
Postretirement healthcare benefit plans	(1,253)	1,539
	<u>\$ 408,647</u>	<u>\$ 321,149</u>

Information regarding benefit obligations, plan assets, funded status, expected cash flows and net periodic benefit cost is as follows:

	<b>Defined Benefit Pension Plans</b>		<b>Postretirement Healthcare Benefit Plans</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
<b>Change in benefit obligations</b>				
Benefit obligations at beginning of year	\$ 9,140,819	\$ 7,433,676	\$ 248,847	\$ 213,043
Service cost	421,338	327,945	3,092	2,887
Interest cost	491,097	472,110	11,844	12,535
Plan amendments (gain)/loss	56,665	(1,197)	-	-
Actuarial (gain)/loss	(362,825)	1,314,353	(6,310)	20,020
Benefits paid	(441,413)	(393,190)	(10,893)	(9,950)
Expenses paid	(13,512)	(12,969)	(1,607)	(1,534)
Employee contributions	87	91	13,366	11,846
Benefit obligations at end of year	<u>\$ 9,292,256</u>	<u>\$ 9,140,819</u>	<u>\$ 258,339</u>	<u>\$ 248,847</u>

The estimated actuarial gain in the change in benefit obligation for 2025 and 2024 is due primarily to the change in discount rate.

The accumulated benefit obligation for all defined benefit pension plans at the end of 2025 and 2024 was \$8,816,878 and \$8,739,071, respectively.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
<b>Weighted-average assumptions used to determine end of year benefit obligation</b>				
Discount rate	5.56%	5.25%	5.08%-5.31%	4.91%-5.05%
Rate of compensation increase	3.00%-5.00%	3.00%-5.00%	N/A	N/A
Interest crediting rate	5.50%	5.50%	5.50%	5.50%
Postretirement healthcare cost trend rate for next year	N/A	N/A	7.25%	7.50%
Rate to which the cost trend rate is to decline	N/A	N/A	5.00%	5.00%
Year that rate reaches the ultimate trend rate	N/A	N/A	2035	2035

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
<b>Change in plan assets</b>				
Fair value of plan assets at beginning of year	\$ 10,325,857	\$ 9,075,320	\$ 225,985	\$ 178,090
Actual return on plan assets	1,525,760	1,549,878	37,866	44,783
Employer contributions	189,514	106,727	2,665	2,750
Employee contributions	87	91	13,366	11,846
Benefits paid	(441,413)	(393,190)	(10,893)	(9,950)
Expenses paid	(13,512)	(12,969)	(1,607)	(1,534)
Fair value of plan assets at end of year	<u>\$ 11,586,293</u>	<u>\$ 10,325,857</u>	<u>\$ 267,382</u>	<u>\$ 225,985</u>

The assets of the defined benefit pension plans are aggregated in a single master trust (Master Trust) and managed as one asset pool. The investment objective for the Master Trust is to achieve the highest reasonable total return after considering (i) plan liabilities, (ii) funding status and projected cash flows, (iii) projected market returns, valuations and correlations for various asset classes and (iv) ability and willingness to incur market risk.

Within the Master Trust, assets are allocated to managers with investment mandates that may range from a single sub-asset class to very broad mandates; with restrictions that range from long-only to unconstrained; and with management structures ranging from separately managed funds to mutual/commingled funds to private partnerships. Less market sensitive managers employ long/short equity and diversified strategies. Investment risks (concentration, correlation, valuation, liquidity, leverage, mandate compliance, etc.) are monitored at the manager level as well as the pool level.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

The following table presents the capital allocations and reported exposures by manager mandate within the Master Trust. Some managers, particularly less market sensitive managers, invest capital among multiple asset classes. The Long-Term Policy Benchmark is 70% Morgan Stanley Capital International All Country World Index and 30% Barclays Global Aggregate Bond.

	September 30, 2025		September 30, 2024	
	Dollars	Reported Exposures	Dollars	Reported Exposures
Global equity	\$ 2,698,413	23.3 %	\$ 1,805,994	17.6 %
Traditional U.S. equity	1,220,395	10.5 %	1,400,147	13.7 %
Traditional foreign developed equity	223,717	1.9 %	195,010	1.9 %
Traditional emerging markets equity	238,931	2.1 %	316,856	3.1 %
Private equity	3,817,388	32.9 %	2,575,951	24.3 %
Real assets	564,024	4.9 %	571,069	5.5 %
Diversifying equity	2,248,278	19.4 %	2,942,049	28.8 %
Fixed income managers	575,147	5.0 %	518,781	5.1 %
	<u>\$ 11,586,293</u>	<u>100.0 %</u>	<u>\$ 10,325,857</u>	<u>100.0 %</u>

The postretirement health care benefit plans' assets are invested in commingled funds with the objective of achieving returns to satisfy plan obligations and with a level of volatility commensurate with our overall financial profile. For the years ended September 30, 2025 and 2024, the defined benefit plans had unfunded commitments of \$1,242,626 and \$1,275,295, respectively.

The following tables summarize plan assets measured at fair value on a recurring basis (using the fair value hierarchy defined in Note 6) as of:

	September 30, 2025			
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	Total
<b>Defined benefit pension plans</b>				
Short-term investments	\$ 360,327	\$ -	\$ -	\$ 360,327
Separately managed investments	1,003,430	3,893	-	1,007,323
Private partnerships and commingled funds	-	-	10,218,643	10,218,643
	1,363,757	3,893	10,218,643	11,586,293
<b>Postretirement healthcare benefit plans</b>				
Separately managed investments	45,149	-	222,233	267,382
Total plan assets	\$ 1,408,906	\$ 3,893	\$ 10,440,876	\$ 11,853,675



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(in thousands of dollars)

	September 30, 2024			
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	Total
<b>Defined benefit pension plans</b>				
Short-term investments	\$ 320,651	\$ -	\$ -	\$ 320,651
Separately managed investments	710,149	-	-	710,149
Private partnerships and commingled funds	-	-	9,295,057	9,295,057
	1,030,800	-	9,295,057	10,325,857
<b>Postretirement healthcare benefit plans</b>				
Separately managed investments	47,332	-	178,653	225,985
Total plan assets	\$ 1,078,132	\$ -	\$ 9,473,710	\$ 10,551,842

In evaluating the Level at which private partnerships have been classified within the fair value hierarchy, management has assessed factors including but not limited to price transparency, the ability to redeem these investments at net asset value at the measurement date and the existence or absence of certain restrictions at the measurement date. Investments in private partnerships generally have limited redemption options for investors and, subsequent to final closing, may or may not permit subscriptions by new or existing investors. These entities may also have the ability to impose gates, lockups and other restrictions on an investor's ability to readily redeem out of their investment interest in the fund. As of September 30, 2025 and 2024, we have excluded all assets from the fair value hierarchy for which fair value is measured using net asset value per share as a practical expedient.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

#### Funded Status

The funded status of the plans recognized in the balance sheet and the amounts recognized in net assets without donor restrictions is as follows:

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
<b>End of year</b>				
Fair value of plan assets at measurement date	\$ 11,586,293	\$ 10,325,857	\$ 267,382	\$ 225,985
Benefit obligations at measurement date	(9,292,256)	(9,140,819)	(258,339)	(248,847)
Funded status	\$ 2,294,037	\$ 1,185,038	\$ 9,043	\$ (22,862)
<b>Amounts recognized in the balance sheet consist of</b>				
Noncurrent asset	\$ 2,315,294	\$ 1,206,988	\$ 23,709	\$ 257
Current liabilities	(4,132)	(1,650)	(1,125)	(1,166)
Long-term liabilities	(17,125)	(20,300)	(13,541)	(21,953)
	\$ 2,294,037	\$ 1,185,038	\$ 9,043	\$ (22,862)
<b>Amounts not yet recognized in net periodic benefit cost and included in net assets without donor restrictions consist of</b>				
Actuarial net gain	\$ (1,376,912)	\$ (184,574)	\$ (47,915)	\$ (19,451)
Prior service (cost)/credit	49,748	(34,197)	(924)	(1,331)
	\$ (1,327,164)	\$ (218,771)	\$ (48,839)	\$ (20,782)
<b>Amounts recognized in net assets without donor restrictions consist of</b>				
Current year actuarial (gain)/loss	\$ (1,192,338)	\$ 422,524	\$ (30,684)	\$ (14,463)
Amortization of actuarial loss	-	8,544	2,679	3,582
Current year prior service cost/(credit)	56,665	(1,197)	-	-
Amortization of prior service credit	27,280	27,127	407	-
	\$ (1,108,393)	\$ 456,998	\$ (27,598)	\$ (10,881)

As of September 30, 2025 and 2024, the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation below plan assets were as follows:

	September 30,	
	2025	2024
<b>Accumulated benefit obligation below plan assets</b>		
Projected benefit obligation	\$ 9,292,256	\$ 9,140,819
Accumulated benefit obligation	8,816,878	8,739,071
Fair value of plan assets	11,586,293	10,325,857



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

#### Expected Cash Flows

Information about the expected cash flows for the defined benefit and postretirement health care benefit plans is as follows:

	Defined Benefit Pension Plans	Postretirement Healthcare Benefit Plans	
<b>Expected employer contributions</b>			
2026	\$ 192,145	\$ 4,333	
			<b>Medicare Subsidy</b>
<b>Expected benefit payments (receipts)</b>			
2026	422,915	19,915	\$ (2)
2027	456,350	20,284	(2)
2028	483,200	20,833	(2)
2029	514,495	21,380	(2)
2030	543,017	21,734	(1)
2031-2034	3,117,186	107,140	(5)

#### Net Periodic Benefit Cost

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
Service cost	\$ 421,338	\$ 327,945	\$ 3,092	\$ 2,887
Interest cost	491,097	472,110	11,844	12,535
Expected return on plan assets	(696,248)	(658,049)	(13,103)	(10,301)
Amortization of				
Prior service credit	(27,280)	(27,127)	(407)	-
Actuarial net gain	-	(8,544)	(2,679)	(3,582)
Nonservice related pension income	(232,431)	(221,610)	(4,345)	(1,348)
Net periodic benefit cost	\$ 188,907	\$ 106,335	\$ (1,253)	\$ 1,539



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2025	2024	2025	2024
<b>Weighted-average assumptions used to determine net periodic pension and postretirement cost</b>				
Discount rate	5.25%	6.22%	4.91%-5.05%	6.07%-6.10%
Expected return on plan assets	7.00%	7.00%	6.00%	6.00%
Interest crediting rate	5.50%	5.25%	5.50%	5.25%-6.50%
Rate of compensation increase	3.00%-5.00%	3.00%-5.00%	N/A	N/A
Healthcare cost trend rate for this year	N/A	N/A	7.50%	6.75%
Rate to which the cost trend rate is to decline	N/A	N/A	5.00%	5.00%
Year that rate reaches the ultimate trend rate	N/A	N/A	2035	2031

We use a long-term return assumption which is validated annually by obtaining long-term asset return, volatility and correlation projections for relevant asset class indexes; modifying volatility and correlations to reflect the actual historical experience of the active managers; calculating the expected return using benchmark weights and indexes; and comparing the return assumption to the sum of the expected return and the historical outperformance of the actual return versus the benchmark. We regularly monitor the active risk of the Master Trust by a statistical regression of the return series of the actual portfolio to that of the policy benchmark.

#### 16. Professional Liability Insurance

We insure substantially all of our professional and general liability risk on a claims-made basis in cooperation with other health care organizations in the Greater Boston area through a reciprocal risk-retention group, Controlled Risk Insurance Company of Vermont, Inc. (CRICO). The Company owns 11% of CRICO. The policies cover claims made during their respective terms, but not those occurrences for which claims may be made after expiration of the policy. Management intends to renew its coverage on a claims-made basis and has no reason to believe that it will be prevented from such renewal. During 2025, CRICO announced and paid a dividend to member organizations. As a result, we recorded dividend income of \$120,595 in other nonoperating expenses.

We follow the accounting policy of establishing reserves to cover the ultimate costs of medical malpractice claims, which include costs associated with litigating or settling claims. The liability also includes an estimated tail liability, established to cover all malpractice claims incurred but not reported to the insurance company as of the end of the year. The total malpractice liability of \$594,421 and \$573,796 as of September 30, 2025 and 2024, respectively, is presented as an accrued professional liability in the consolidated balance sheets. These reserves have been recorded on a discounted basis using an interest rate of 5.0% as of September 30, 2025 and 2024.

We also recognize an insurance receivable from CRICO at the same time that we recognize the liability, measured on the same basis as the liability, subject to the need for a valuation allowance for uncollectible amounts. The insurance receivable of \$464,510 and \$442,072 as of September 30, 2025 and 2024, respectively, is reported as a component of other assets in the consolidated balance sheets.



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

*(in thousands of dollars)*

Management is not aware of any claims against us or factors affecting CRICO that would cause the expense for professional liability risks to vary materially from the amount provided.

#### **17. Concentration of Credit Risk**

Financial instruments that potentially subject us to concentration of credit risk consist of patient accounts receivable, research grants receivable, pledges receivable, premiums receivable, certain investments and interest rate swaps.

Mass General Brigham provider organizations receive a significant portion of payments for services rendered from a limited number of government and commercial third-party payers, including Medicare, Medicaid, Blue Cross and Blue Shield of Massachusetts, and Point32Health. Research funding is provided through many government and private sponsors. The Health Plan receives a portion of premium revenue from the Commonwealth.

Pledges receivable are due from multiple donors. We assess the credit risk for pledges based on history and the financial wherewithal of donors, most of which are individuals or organizations well known to us.

Investments, which include government and agency securities, stocks and corporate bonds, private partnerships and other investments, are not concentrated in any corporation or industry or with any single counterparty. Alternative investments are less liquid than other investments. The reported values of the alternative investments may differ significantly from the values that would have been used had a ready market for those securities existed. These instruments may contain elements of both credit and market risk. Such risks include, but are not limited to, limited liquidity, absence of oversight, dependence upon key individuals, emphasis on speculative investments and nondisclosure of portfolio composition.

We minimize our credit risk exposure under interest rate swap agreements by utilizing several counterparties and requiring the counterparties to post collateral for our benefit when the fair value of the swap is positive. We minimize our counterparty risk by contracting with nine counterparties, none of which accounts for more than 21% of the aggregate notional amount of the swap contracts.



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(in thousands of dollars)

**18. Net Assets**

**Net assets without donor restrictions**

The following table reconciles the changes in consolidated net assets without donor restrictions that are attributable to the Company and noncontrolling interests:

	<b>Controlling Interest</b>	<b>Noncontrolling Interest</b>	<b>Total</b>
<b>Net assets without donor restrictions at September 30, 2023</b>	<u>\$ 13,266,506</u>	<u>\$ 95,939</u>	<u>\$ 13,362,445</u>
Excess of revenues over expenses	2,051,883	(4,204)	2,047,679
Funds utilized for property and equipment	434,073	-	434,073
Change in funded status of defined benefit plans	(445,729)	-	(445,729)
Other changes in net assets	69	15,053	15,122
Increase in net assets without donor restriction	<u>2,040,296</u>	<u>10,849</u>	<u>2,051,145</u>
<b>Net assets without donor restrictions at September 30, 2024</b>	<u>15,306,802</u>	<u>106,788</u>	<u>15,413,590</u>
Excess of revenues over expenses	2,396,553	(10,911)	2,385,642
Funds utilized for property and equipment	36,549	-	36,549
Change in funded status of defined benefit plans	1,135,994	-	1,135,994
Other changes in net assets	(1,253)	(2,224)	(3,477)
Increase in net assets without donor restriction	<u>3,567,843</u>	<u>(13,135)</u>	<u>3,554,708</u>
<b>Net assets without donor restrictions at September 30, 2025</b>	<u>\$ 18,874,645</u>	<u>\$ 93,653</u>	<u>\$ 18,968,298</u>

**Net assets with donor restrictions**

Net assets with donor restrictions are available for the following purposes:

	<b>September 30,</b>	
	<b>2025</b>	<b>2024</b>
<b>Net assets with donor restrictions</b>		
Charity care	\$ 233,182	\$ 223,251
Buildings and equipment	682,102	506,830
Clinical care, research and academic	3,727,987	3,216,044
	<u>\$ 4,643,271</u>	<u>\$ 3,946,125</u>



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

---

(in thousands of dollars)

#### Endowment

Our endowment consists of numerous individual funds established for a variety of purposes and includes both endowment funds with donor restrictions and funds designated by boards to function as endowment. We have interpreted UPMIFA as requiring the preservation of the value of the original contribution of the endowment funds with donor restrictions absent explicit donor stipulations to the contrary. As a result of this interpretation, we classify net assets with donor restrictions, the original value of all contributions with donor stipulations to maintain in perpetuity, accumulated gains required to be maintained in perpetuity by explicit donor stipulation or accumulated gains which have been appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, we consider several factors in making a determination to appropriate or accumulate endowment funds with donor restrictions. These factors include: the duration and preservation of the fund; the purposes of the organization and the endowment fund with donor restrictions; general economic conditions; the possible effect of inflation and deflation; the expected total return from income and the appreciation of investments; other resources of the organization; and the investment policies of the organization.

#### Endowment Funds with Deficits

From time to time, the value of assets associated with individual endowment funds with donor restrictions may fall below the value of the initial and subsequent donor contribution amounts. These deficits generally result from unfavorable market fluctuations that occurred after the investment of new contributions with donor restrictions or subsequent endowment additions. When such endowment deficits exist, they are classified as a reduction to net assets with donor restrictions.

The following presents the endowment net asset composition by type of fund as of September 30, 2025 and 2024 and the changes in endowment assets for the years ended September 30, 2025 and 2024:

	Without Donor Restrictions	With Donor Restrictions	Total
<b>Endowment net asset composition by type of fund as of September 30, 2025</b>			
Endowment funds with donor restrictions	\$ -	\$ 3,356,694	\$ 3,356,694
Endowment funds with board designations	1,936,933	-	1,936,933
Total funds	<u>\$ 1,936,933</u>	<u>\$ 3,356,694</u>	<u>\$ 5,293,627</u>



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

---

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	Total
<b>Changes in endowment net assets</b>			
<b>Endowment net assets at September 30, 2024</b>	<u>\$ 1,662,338</u>	<u>\$ 2,929,226</u>	<u>\$ 4,591,564</u>
Investment return			
Investment income	3,508	6,078	9,586
Net realized and unrealized appreciation	<u>251,118</u>	<u>436,482</u>	<u>687,600</u>
Total investment return	254,626	442,560	697,186
Contributions	30,447	150,736	181,183
Appropriation of endowment assets for expenditure	(8,922)	(163,618)	(172,540)
Other changes	<u>(1,556)</u>	<u>(2,210)</u>	<u>(3,766)</u>
Total changes	<u>274,595</u>	<u>427,468</u>	<u>702,063</u>
<b>Endowment net assets at September 30, 2025</b>	<u>\$ 1,936,933</u>	<u>\$ 3,356,694</u>	<u>\$ 5,293,627</u>

	Without Donor Restrictions	With Donor Restrictions	Total
<b>Endowment net asset composition by type of fund as of September 30, 2024</b>			
Endowment funds with donor restrictions	\$ -	\$ 2,929,226	\$ 2,929,226
Endowment funds with board designations	<u>1,662,338</u>	<u>-</u>	<u>1,662,338</u>
Total funds	<u>\$ 1,662,338</u>	<u>\$ 2,929,226</u>	<u>\$ 4,591,564</u>



**Mass General Brigham Incorporated and Affiliates**  
**Notes to Consolidated Financial Statements**  
**September 30, 2025 and 2024**

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	Total
<b>Changes in endowment net assets</b>			
<b>Endowment net assets at September 30, 2023</b>	<u>\$ 1,368,005</u>	<u>\$ 2,441,991</u>	<u>\$ 3,809,996</u>
Investment return			
Investment income	1,660	2,851	4,511
Net realized and unrealized appreciation	<u>261,492</u>	<u>452,078</u>	<u>713,570</u>
Total investment return	263,152	454,929	718,081
Contributions	10,624	142,349	152,973
Appropriation of endowment assets for expenditure	(61,076)	(107,076)	(168,152)
Other changes	<u>81,633</u>	<u>(2,967)</u>	<u>78,666</u>
Total changes	<u>294,333</u>	<u>487,235</u>	<u>781,568</u>
<b>Endowment net assets at September 30, 2024</b>	<u>\$ 1,662,338</u>	<u>\$ 2,929,226</u>	<u>\$ 4,591,564</u>

**19. Functional Expenses**

Expenses by functional classification are allocated based on management's judgement, the nature of the expense and historical experience. Such classifications and allocations are as follows:

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2025
<b>Operating expenses</b>					
Employee compensation and benefit expense	\$ 9,461,923	\$ -	\$ 69,376	\$ 1,591,615	\$ 11,122,914
Supplies and other expenses	6,115,688	-	101,667	307,546	6,524,901
Medical claims and related expenses	-	-	1,819,473	-	1,819,473
Direct research and nonresearch sundry expenses	-	2,324,147	-	-	2,324,147
Depreciation and amortization expenses	704,019	-	53	87,680	791,752
Interest expense	103,486	-	-	61,920	165,406
Total operating expenses	<u>\$ 16,385,116</u>	<u>\$ 2,324,147</u>	<u>\$ 1,990,569</u>	<u>\$ 2,048,761</u>	<u>\$ 22,748,593</u>

Direct research and nonresearch sundry expenses include \$1,432,864 of employee compensation and benefit expense and \$891,283 of supplies and other expenses for the year ended September 30, 2025.

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2025
<b>Nonoperating expenses</b>					
Employee compensation and benefit expense	\$ -	\$ -	\$ -	\$ 84,342	\$ 84,342
Supplies and other expenses	-	-	-	35,950	35,950
Interest expense	-	-	-	19,010	19,010
Pension related interest costs	384,125	51,401	-	67,415	502,941
Total nonoperating expenses	<u>\$ 384,125</u>	<u>\$ 51,401</u>	<u>\$ -</u>	<u>\$ 206,717</u>	<u>\$ 642,243</u>



# Mass General Brigham Incorporated and Affiliates

## Notes to Consolidated Financial Statements

### September 30, 2025 and 2024

(in thousands of dollars)

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2024
<b>Operating expenses</b>					
Employee compensation and benefit expense	\$ 8,762,016	\$ -	\$ 82,892	\$ 1,419,870	\$ 10,264,778
Supplies and other expenses	5,182,240	-	94,827	263,209	5,540,276
Medical claims and related expenses	-	-	1,505,038	-	1,505,038
Direct research and nonresearch sundry expenses	-	2,240,832	-	-	2,240,832
Depreciation and amortization expenses	691,739	-	-	86,598	778,337
Interest expense	100,276	-	-	75,003	175,279
Total operating expenses	<u>\$ 14,736,271</u>	<u>\$ 2,240,832</u>	<u>\$ 1,682,757</u>	<u>\$ 1,844,680</u>	<u>\$ 20,504,540</u>

Direct research and nonresearch sundry expenses include \$1,339,705 of employee compensation and benefit expense and \$901,127 of supplies and other expenses for the year ended September 30, 2024.

	Healthcare Services	Research and Nonresearch Sundry	Insurance	General and Administrative	Year Ended September 30, 2024
<b>Nonoperating expenses</b>					
Employee compensation and benefit expense	\$ -	\$ -	\$ -	\$ 85,449	\$ 85,449
Supplies and other expenses	-	-	-	24,244	24,244
Interest expense	-	-	-	57,567	57,567
Pension related interest costs	368,476	52,972	-	63,197	484,645
Total nonoperating expenses	<u>\$ 368,476</u>	<u>\$ 52,972</u>	<u>\$ -</u>	<u>\$ 230,457</u>	<u>\$ 651,905</u>

## 20. Contingencies

We are subject to complaints, claims and litigation which arise in the normal course of business. In addition, we are subject to reviews and investigations by various federal and state government agencies to assure compliance with applicable laws, some of which are subject to different interpretations. Governmental review of compliance by health care organizations has increased.

## 21. Subsequent Events

We have assessed the impact of subsequent events through December 19, 2025, the date the audited financial statements were issued. During this period, there were no subsequent events that require adjustment to the audited financial statements.